QGA
CLDI.WS

Q Global Advisors’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Q Global Advisors’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$50K – 339
2021
Q4 		$50K Buy
+100,000
New +$56.4K 0.01% 165

Other funds holding CLDI.WS

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Q Global Advisors's CLDI.WS Position: Q1 2022 in Review

Q Global Advisors sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q1 2022, closing a stake of 100,000 shares — an estimated $50K sold.

Q Global Advisors first reported a position in CLDI.WS in Q4 2021 and held it in 1 quarter. The position peaked at $50K in Q4 2021. 27 funds tracked by Wall St. Rank hold CLDI.WS as of Q1 2022.

  • Q Global Advisors reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q1 2022 after selling out during the quarter.
  • Q Global Advisors sold 100,000 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q1 2022, an estimated $50K.
  • Q Global Advisors first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 1 quarter.
  • Q Global Advisors's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $50K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q1 2022.

Based on Q Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.